Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00602030 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Non-Small-Cell Lung Carcinoma, sponsored by Syndax Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
141
Enrollment target
20
Study locations

NCT00602030 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Non-Small-Cell Lung Carcinoma that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 141 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00602030, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Non-Small-Cell Lung Carcinoma, has completed, sponsored by Syndax Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
141 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

Conditions Studied

Carcinoma, Non-Small Cell Lung Non-Small-Cell Lung Carcinoma

Interventions

  • DRUG Placebo
  • DRUG Entinostat
  • DRUG Erlotinib

Study Locations (20)

Texas

  • Texas Oncology - Amarillo
  • Texas Oncology - Austin
  • Texas Oncology - Bedford
  • Texas Oncology, Sammons Cancer Center - Dallas
  • Texas Oncology - Dallas
  • Texas Oncology - Fort Worth

Florida

  • Advanced Medical Specialties - Miami
  • Ocala Oncology Center - Ocala
  • Cancer Centers of Florida - Ocoee

Missouri

  • St Joseph Oncology - Saint Joseph
  • The Center for Cancer Care & Research - St Louis

Ohio

  • Mahonig Valley Hematology Oncology Associates - Boardman
  • Dayton Oncology & Hematology - Kettering

Arizona

  • HOPE (Hematology Oncology Physicians & Extenders) - Tucson

Colorado

  • Rocky Mountain Cancer Center - Denver

Illinois

  • Hematology Oncology Associates of Illinois - Chicago

Indiana

  • Central Indiana Cancer Centers - Indianapolis

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2008-01-08
Est. Completion 2012-02-01
Phase Phase 1

Sponsor

Syndax Pharmaceuticals

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00602030

The ClinicalTrials.gov registry entry for NCT00602030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (56% lower). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00602030 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT00602030 about?

NCT00602030 is a clinical study titled "Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC". The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

What is the current status of trial NCT00602030?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2008-01-08. Estimated completion is 2012-02-01.

What conditions does trial NCT00602030 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Non-Small-Cell Lung Carcinoma.

What interventions are being tested in trial NCT00602030?

The interventions under investigation include: Placebo (DRUG), Entinostat (DRUG), Erlotinib (DRUG).

Who is sponsoring clinical trial NCT00602030?

This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00602030 being conducted?

This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Non-Small-Cell Lung Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.